Category Archives: Pharma & Biotech

Pharma & Biotech Press Releases & News distributed via EuropaWire

Tezspire Shows Promise in Reducing Nasal Polyp Symptoms in Phase III Trial for Chronic Rhinosinusitis

(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients with chronic rhinosinusitis with nasal polyps (CRSwNP), reducing both nasal polyp size and congestion compared to a placebo. The WAYPOINT trial … Read the full press release

Logicor Renews Lease with DHL Poland, Expanding Pharmaceutical Logistics Hub in Mysłowice

(IN BRIEF) Logicor has extended its lease with DHL Poland at its Mysłowice logistics park, where DHL occupies 12,200 sqm of warehouse space and provides logistical support for Bausch Health Poland. The facility, tailored for pharmaceutical needs with advanced temperature … Read the full press release

EMA Approves Dupixent as First-Ever Treatment for Young Children with Eosinophilic Esophagitis in the EU

(IN BRIEF) The European Medicines Agency has approved Dupixent as the first treatment for eosinophilic esophagitis (EoE) in young children aged one to 11, marking a significant step in managing this condition in a critical developmental phase. The approval is … Read the full press release

SGS Boosts Pharmaceutical Spray Testing with Cutting-Edge Laser Diffraction Technology in Belgium

(IN BRIEF) SGS has introduced advanced laser diffraction technology at its Wavre, Belgium lab, enhancing its ability to measure droplet sizes in spray drug delivery systems. This investment in Malvern Spraytec technology allows for real-time data collection during the spray … Read the full press release

Evotec Sells API Manufacturing Site to Monacum Partners, Streamlining Focus on Core Growth Areas

(IN BRIEF) Evotec SE has sold its chemical API-focused manufacturing site, Evotec DS GmbH, to Monacum Partners as part of its “Priority Reset” strategy to focus on core growth areas. The Halle/Westphalia-based facility, now renamed DAPIN GmbH, will continue its … Read the full press release

FDA Clears QIAGEN’s Rapid QIAstat-Dx Panel for Meningitis and Encephalitis Diagnosis, Expanding Syndromic Test Portfolio

(IN BRIEF) QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel has received FDA clearance, enabling faster and more accurate diagnosis of critical CNS infections like meningitis and encephalitis. This panel, the fourth QIAstat-Dx test approved in the U.S. in 2024, uses real-time PCR to … Read the full press release

Accenture and 1910 Genetics Unite to Revolutionize Drug Discovery with AI-Driven Solutions

(IN BRIEF) Accenture has invested in 1910 Genetics, a biotech firm leveraging AI-driven lab automation to enhance drug discovery for small and large molecule therapies. This partnership aims to provide biopharma clients with a powerful AI platform, streamlining the drug … Read the full press release

Roche’s Itovebi Regimen Shows Significant Survival Benefits for HR-Positive Breast Cancer in Phase III Trial Results

(IN BRIEF) Roche announced the publication of pivotal phase III results for its Itovebi™ (inavolisib)-based regimen at the Clinical Trials in Alzheimer’s Disease congress, demonstrating a 57% reduction in the risk of disease progression or death in patients with HR-positive, … Read the full press release

Roche Showcases Advancements in Alzheimer’s Diagnostics at CTAD 2024

(IN BRIEF) At the CTAD 2024 congress in Madrid, Roche presented new data on its Elecsys® Amyloid Plasma Panel and Elecsys ptau181, demonstrating their effectiveness in diagnosing Alzheimer’s disease. The blood-based test showed a negative predictive value of 96.2% in … Read the full press release

QIAGEN Gains FDA Approval for QIAstat-Dx Mini Panel, Enhancing Outpatient Respiratory Diagnostics with Rapid Results

(IN BRIEF) QIAGEN has announced FDA clearance for its QIAstat-Dx Respiratory Panel Mini, marking the third such approval for the QIAstat-Dx system in 2024. Tailored for outpatient settings, this panel quickly detects five common respiratory pathogens—including influenza strains and SARS-CoV-2—enabling … Read the full press release

AstraZeneca’s Fasenra Approved in EU for Treating Rare Vasculitis, Offering New Hope for EGPA Patients

(IN BRIEF) AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare and severe form of vasculitis. The approval follows positive results from the MANDARA Phase … Read the full press release

Wainzua Receives EU Recommendation for Treating Hereditary Amyloidosis, Offering New Monthly Self-Administered Option

(IN BRIEF) AstraZeneca and Ionis’ drug Wainzua (eplontersen) has been recommended for approval in the European Union for treating hereditary transthyretin-mediated amyloidosis (ATTRv-PN) in adults with stage 1 or 2 polyneuropathy. Based on the positive results from the NEURO-TTRansform Phase … Read the full press release

GSK and Cambridge University Join Forces with £50 Million Investment to Tackle Kidney and Respiratory Diseases Using AI

(IN BRIEF) GSK and the University of Cambridge have announced a £50 million, five-year collaboration called the Cambridge-GSK Translational Immunology Collaboration (CG-TIC) to accelerate research and development in kidney and respiratory diseases. The initiative combines GSK’s expertise in immunology and … Read the full press release

Novo Nordisk’s Oral Semaglutide Reduces Cardiovascular Risk by 14% in Type 2 Diabetes Patients, SOUL Trial Shows

(IN BRIEF) Novo Nordisk’s SOUL trial has shown that oral semaglutide reduces the risk of major adverse cardiovascular events (MACE) by 14% in adults with type 2 diabetes and established cardiovascular disease or chronic kidney disease. The trial involved 9,650 … Read the full press release

Sanofi and CD&R Join Forces to Propel Opella’s Global Consumer Healthcare Expansion

(IN BRIEF) Sanofi and CD&R have entered exclusive negotiations for CD&R to acquire a 50% controlling stake in Opella, Sanofi’s consumer healthcare business, while Sanofi retains a significant share. The partnership aims to support Opella’s growth as a global leader … Read the full press release

Novo Nordisk’s Alhemo® Recommended for European Approval as First Once-Daily Subcutaneous Treatment for Haemophilia A and B with Inhibitors

(IN BRIEF) Novo Nordisk’s Alhemo® (concizumab) has been recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). If approved, Alhemo® will become the first once-daily subcutaneous prophylactic treatment for people aged 12 … Read the full press release

Sanofi and Orano Med Partner to Drive Development of Advanced Radioligand Cancer Therapies

(IN BRIEF) Sanofi and Orano Med have partnered to accelerate the development of next-generation radioligand therapies (RLTs) for rare cancers. By combining their expertise, they aim to advance treatments using lead-212 (212Pb) alpha-emitting isotopes, which target and destroy cancer cells … Read the full press release

OMRON Healthcare introduceert nieuwe bloeddrukmeters met AI-aangedreven AFib-detectietechnologie; lancering in Europa september 2024

HET NIEUWE INTELLISENSE AFIB-ALGORITME ONTDEKT MOGELIJKE ATRIUMFIBRILLATIE BIJ ELKE CONTROLE VAN DE BLOEDDRUK, VERBETERT VROEGE DETECTIE EN MOGELIJKE PREVENTIE VAN ERNSTIGE COMPLICATIES (IN HET KORT) OMRON Healthcare introduceert nieuwe bloeddrukmeters met een door AI aangedreven technologie voor het detecteren van … Read the full press release

OMRON Healthcare dévoile de nouveaux tensiomètres dotés d’une technologie de détection de la fibrillation auriculaire alimentée par l’IA, lancés en Europe en septembre 2024

LE NOUVEL ALGORITHME INTELLISENSE AFIB DÉTECTE UNE ÉVENTUELLE FIBRILLATION AURICULAIRE LORS DE CHAQUE CONTRÔLE DE LA PRESSION ARTÉRIELLE, AMÉLIORANT AINSI LA DÉTECTION PRÉCOCE ET LA PRÉVENTION ÉVENTUELLE DE COMPLICATIONS GRAVES (ACTUALITÉ EN BREF) OMRON Healthcare a dévoilé une nouvelle gamme … Read the full press release

OMRON Healthcare presenta i nuovi misuratori della pressione sanguigna con tecnologia di rilevamento della fibrillazione atriale (AFib) basata sull’IA, in arrivo in Europa a settembre 2024

IL NUOVO ALGORITMO INTELLISENSE AFIB RILEVA UNA POSSIBILE FIBRILLAZIONE ATRIALE AD OGNI CONTROLLO DELLA PRESSIONE SANGUIGNA, INCREMENTANDO LE POSSIBILITÀ DI RILEVAZIONE PRECOCE E PREVENZIONE DI COMPLICAZIONI POTENZIALMENTE GRAVI (NOTIZIA IN BREVE) OMRON Healthcare ha lanciato una nuova gamma di misuratori … Read the full press release